Lianhuan Pharmaceutical: The company has obtained approval notices for clinical trials of two improved new drugs.

Lehmann Pharmaceutical announced that it has recently received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for the two-improved new drug LH-2417 tablets. The company will soon start clinical trials. LH-2417 tablets are used for the initial treatment of signs and symptoms of benign prostatic hyperplasia in men with enlarged prostate.